Login to Your Account



Financings NEWS

After several years incubating in the Centre for Probe Development and Commercialization at McMaster University in Hamilton, Ontario, Fusion Pharmaceuticals Inc. is hanging out its shingle.

DUBLIN – Prexton Therapeutics SA raised €29 million in a series B round to conduct two phase II trials in Parkinson’s disease of its metabotropic glutamate receptor 4 (mGluR4) agonist, foliglurax (PXT002331).

Three-year-old Chondrial Therapeutics Inc. scored a series A financing of up to $22.6 million and licensed its first asset in a quest to build a pipeline of therapies to treat rare mitochondrial diseases.

More Financings Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: